Portfolio company
Epicyt
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This pharmaceutical company develops a drug candidate to improve intestinal calcium absorption for patients who have undergone gastric bypass surgery.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Epicyt Pharma
This company develops pharmaceutical treatments to restore intestinal calcium absorption for patients with osteoporosis or those who have undergone gastric bypass surgery.
Cinclus Pharma
This biopharmaceutical company develops small molecule drugs for patients suffering from gastric acid-related diseases, including erosive gastroesophageal reflux disease.
Moroxite F
This company develops regenerative medicine solutions to improve implant anchorage in osteoporotic bone for patients undergoing orthopaedic surgery.
Ousia Pharma
This biotechnology company develops peptide-drug conjugates to treat obesity and cardiometabolic diseases for patients requiring improved metabolic health and weight regulation.
Sanifit
This biopharmaceutical company develops treatments for progressive vascular calcification disorders in patients with end-stage kidney disease.
Epoqe Pharma
The company develops peptide-based heart rescue therapies to treat acute myocardial infarction for patients with cardiovascular diseases.
Epigenica
This company develops epigenetic analysis kits and screening tools for researchers in drug discovery, diagnostics, and precision medicine.
Skeletalis
This biotechnology company develops bone-targeted small-molecule therapies for patients with osteoporosis and other musculoskeletal diseases.
